CY1109607T1 - Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων - Google Patents

Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων

Info

Publication number
CY1109607T1
CY1109607T1 CY20091101180T CY091101180T CY1109607T1 CY 1109607 T1 CY1109607 T1 CY 1109607T1 CY 20091101180 T CY20091101180 T CY 20091101180T CY 091101180 T CY091101180 T CY 091101180T CY 1109607 T1 CY1109607 T1 CY 1109607T1
Authority
CY
Cyprus
Prior art keywords
progressing
radiotherapy
cancer
treatment
diseases
Prior art date
Application number
CY20091101180T
Other languages
Greek (el)
English (en)
Inventor
John David Rothermel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1109607T1 publication Critical patent/CY1109607T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silicon Polymers (AREA)
CY20091101180T 2002-05-01 2009-11-11 Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων CY1109607T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37706302P 2002-05-01 2002-05-01
EP03725129A EP1503756B1 (en) 2002-05-01 2003-04-30 Epothilone derivative for the treatment of hepatoma and other cancer diseases

Publications (1)

Publication Number Publication Date
CY1109607T1 true CY1109607T1 (el) 2014-08-13

Family

ID=29401440

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101180T CY1109607T1 (el) 2002-05-01 2009-11-11 Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων

Country Status (23)

Country Link
US (2) US20050282873A1 (enExample)
EP (1) EP1503756B1 (enExample)
JP (1) JP2005528414A (enExample)
KR (1) KR20040106422A (enExample)
CN (1) CN1649585A (enExample)
AT (1) ATE439130T1 (enExample)
AU (1) AU2003227702B2 (enExample)
BR (1) BR0309711A (enExample)
CA (1) CA2483826C (enExample)
CY (1) CY1109607T1 (enExample)
DE (1) DE60328772D1 (enExample)
DK (1) DK1503756T3 (enExample)
ES (1) ES2330324T3 (enExample)
IL (1) IL164783A (enExample)
MX (1) MXPA04010853A (enExample)
NO (1) NO20045249L (enExample)
NZ (1) NZ536178A (enExample)
PL (1) PL211114B1 (enExample)
PT (1) PT1503756E (enExample)
RU (1) RU2358730C2 (enExample)
SI (1) SI1503756T1 (enExample)
WO (1) WO2003092683A1 (enExample)
ZA (1) ZA200408492B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
WO2006055742A1 (en) * 2004-11-18 2006-05-26 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.
MX2008004268A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 24 horas.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
EE04852B1 (et) * 1999-02-22 2007-06-15 Gesellschaft Fuer Biotechnologische Forschung Mbh C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
GB9918429D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
CN1649585A (zh) * 2002-05-01 2005-08-03 诺瓦提斯公司 用于治疗肝脏肿瘤和其它癌症疾病的埃坡霉素衍生物

Also Published As

Publication number Publication date
BR0309711A (pt) 2005-02-09
IL164783A (en) 2011-08-31
RU2358730C2 (ru) 2009-06-20
CA2483826C (en) 2012-04-17
MXPA04010853A (es) 2005-02-14
PL371727A1 (en) 2005-06-27
DE60328772D1 (de) 2009-09-24
US20050282873A1 (en) 2005-12-22
AU2003227702A1 (en) 2003-11-17
EP1503756B1 (en) 2009-08-12
PT1503756E (pt) 2009-10-28
JP2005528414A (ja) 2005-09-22
ZA200408492B (en) 2006-09-27
NO20045249L (no) 2005-01-26
HK1073601A1 (en) 2005-10-14
ES2330324T3 (es) 2009-12-09
US20080161369A1 (en) 2008-07-03
WO2003092683A1 (en) 2003-11-13
SI1503756T1 (sl) 2010-01-29
DK1503756T3 (da) 2009-11-16
IL164783A0 (en) 2005-12-18
NZ536178A (en) 2007-10-26
EP1503756A1 (en) 2005-02-09
KR20040106422A (ko) 2004-12-17
AU2003227702B2 (en) 2007-07-26
ATE439130T1 (de) 2009-08-15
PL211114B1 (pl) 2012-04-30
CA2483826A1 (en) 2003-11-13
CN1649585A (zh) 2005-08-03
RU2004135307A (ru) 2005-09-10

Similar Documents

Publication Publication Date Title
PH12019502586A1 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
RU2012140185A (ru) Ингибирование ангиогенеза
NO20051575L (no) Bruk av quinazolinderivatet ZD6474 i kombinasjon med gemcitabin og valgfritt ioniserende straling i behandling av sykdommer forbundet med angiogenese og/eller okt kar-gjennomtrengelighet
BR0309711A (pt) Método para o tratamento de doenças do câncer
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
EA201201154A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
RU2018102963A (ru) Производные анилинпиримидина и их применения
RU2003137007A (ru) Новые пиридилцианогуанидиновые соединения
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
SG170809A1 (en) Diarylthiohydantoin compounds
CN110678452A (zh) 亚精胺及其衍生物的应用
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
JOP20240269A1 (ar) حلقات كبيرة من إندازول و استخدامها
RU2013131241A (ru) Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака
ATE424208T1 (de) Proteinkinaseinhibitoren
ATE353650T1 (de) Kombinationstherapie zur behandlung von krebs
DE602005015304D1 (de) Krebstherapie mit einem nukleären rezeptorliganden und einem hdac-hemmer
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
JP2023517671A5 (enExample)
PL1653964T3 (pl) Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
DE50211672D1 (de) Urokinase-inhibitoren
NO20064754L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi